Skip to content
News
Anal Cancer
Bladder Cancer
Bone Cancer
Brain Cancer
Breast Cancer
Cancer of Unknown Primary
Cervical Cancer
Colon Cancer
Esophageal Cancer
Gastric Cancer
GIST
Head & Neck Cancer
Hodgkins Lymphoma
Leukemia
Acute Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Liver Cancer
Lung Cancer
Melanoma
Mesothelioma
Multiple Myeloma
Myelodysplastic Syndrome
MPN-PV-ET-MF
Neuroblastoma
Neuroendocrine Tumors
Non Hodgkins Lymphoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Renal Cancer
Rectal Cancer
Sarcoma
Skin Care
Skin Cancer
Testicular Cancer
Thyroid Cancer
Triple Negative Breast Cancer
Uterine Cancer
About Us
Advertising
News
Newly Diagnosed
Treatment & Care
Survivorship
Join the Community
Newsletter
Search
Uncategorized
March 29, 2026
ctDNA Blood Test May Help Predict Anal Cancer Recurrence After Chemoradiation
Dr. C H Weaver MD
January 28, 2026
New Latitude Blood Test Expands MRD Access Beyond Tumor Tissue–Dependent Options in Colorectal Cancer
Dr. C H Weaver MD
December 19, 2025
The Big Picture: Medical Breakthroughs in 2025
Dr. C H Weaver MD
December 15, 2025
New Research at ASH 2025 Points to More Targeted and Personalized Care for People with MPNs
Dr. C H Weaver MD
December 8, 2025
FDA Approves New Blood Test to Help Diagnose High-Grade Prostate Cancer
Meg Monday
November 21, 2025
GLP‑1 Drugs Linked to Better 5‑Year Survival in Colon Cancer Patients With Severe Obesity
Dr. C H Weaver MD
July 7, 2025
Breastfeeding for At Least Six Months May Help Lower Risk of Aggressive Breast Cancer
Dr. C H Weaver MD
June 24, 2025
FDA Expands Monjuvi Approval to Include Relapsed or Refractory Follicular Lymphoma
Dr. C H Weaver MD
June 23, 2025
FDA Grants Accelerated Approval for Datroway in EGFR-Mutated Non-Small Cell Lung Cancer
Dr. C H Weaver MD
June 18, 2025
Promising Results for Bexmarilimab Plus Azacitidine in High-Risk MDS
Dr. C H Weaver MD
June 17, 2025
FDA Approves First Nonsurgical Treatment for Recurrent, Low-Grade, Intermediate-Risk NMIBC
Dr. C H Weaver MD
June 16, 2025
FDA Approves Talectrectinib (Ibtrozi) for ROS1-Positive Lung Cancer
Dr. C H Weaver MD
1
2
Next Page
Loading Comments...
Write a Comment...
Email (Required)
Name (Required)
Website
